Chase Investment Counsel Corp Purchases 11,912 Shares of DaVita Inc. (NYSE:DVA)

Chase Investment Counsel Corp increased its position in shares of DaVita Inc. (NYSE:DVA) by 56.3% during the third quarter, according to its most recent filing with the Securities & Exchange Commission. The fund owned 33,084 shares of the company’s stock after acquiring an additional 11,912 shares during the period. DaVita comprises about 1.8% of Chase Investment Counsel Corp’s portfolio, making the stock its 19th biggest position. Chase Investment Counsel Corp’s holdings in DaVita were worth $5,423,000 at the end of the most recent reporting period.

Other institutional investors and hedge funds have also bought and sold shares of the company. Bessemer Group Inc. raised its position in shares of DaVita by 2,335.6% in the 1st quarter. Bessemer Group Inc. now owns 10,741 shares of the company’s stock worth $1,483,000 after acquiring an additional 10,300 shares in the last quarter. Sei Investments Co. grew its stake in shares of DaVita by 21.3% in the 1st quarter. Sei Investments Co. now owns 41,952 shares of the company’s stock valued at $5,790,000 after buying an additional 7,371 shares during the period. BOKF NA raised its stake in DaVita by 286,550.0% during the 1st quarter. BOKF NA now owns 5,733 shares of the company’s stock worth $790,000 after buying an additional 5,731 shares during the period. Oppenheimer & Co. Inc. bought a new position in DaVita in the first quarter worth approximately $703,000. Finally, Assenagon Asset Management S.A. increased its holdings in shares of DaVita by 29.6% during the second quarter. Assenagon Asset Management S.A. now owns 50,096 shares of the company’s stock valued at $6,942,000 after acquiring an additional 11,454 shares in the last quarter. Institutional investors and hedge funds own 90.12% of the company’s stock.

Insider Transactions at DaVita

In other DaVita news, CEO Javier Rodriguez sold 32,176 shares of the business’s stock in a transaction on Monday, August 26th. The stock was sold at an average price of $155.93, for a total value of $5,017,203.68. Following the sale, the chief executive officer now directly owns 905,659 shares in the company, valued at $141,219,407.87. The trade was a 0.00 % decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is available through the SEC website. In related news, CEO Javier Rodriguez sold 32,176 shares of the company’s stock in a transaction that occurred on Monday, August 26th. The shares were sold at an average price of $155.93, for a total transaction of $5,017,203.68. Following the sale, the chief executive officer now directly owns 905,659 shares in the company, valued at approximately $141,219,407.87. This represents a 0.00 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CFO Joel Ackerman sold 64,029 shares of DaVita stock in a transaction that occurred on Tuesday, August 27th. The shares were sold at an average price of $155.06, for a total transaction of $9,928,336.74. Following the completion of the transaction, the chief financial officer now owns 111,481 shares of the company’s stock, valued at $17,286,243.86. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 165,625 shares of company stock worth $26,238,297 in the last quarter. Insiders own 2.00% of the company’s stock.

Analyst Ratings Changes

DVA has been the subject of a number of recent research reports. TD Cowen boosted their price target on shares of DaVita from $139.00 to $150.00 and gave the company a “hold” rating in a research note on Wednesday, July 24th. Truist Financial raised their price target on shares of DaVita from $165.00 to $175.00 and gave the company a “hold” rating in a research report on Monday, October 7th. UBS Group boosted their price objective on DaVita from $169.00 to $175.00 and gave the stock a “buy” rating in a report on Thursday, August 8th. Barclays raised their target price on DaVita from $150.00 to $164.00 and gave the company an “equal weight” rating in a report on Thursday, October 31st. Finally, Bank of America upped their price target on DaVita from $139.00 to $145.00 and gave the stock an “underperform” rating in a report on Wednesday, August 7th. One analyst has rated the stock with a sell rating, three have issued a hold rating and two have issued a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $161.80.

DaVita Stock Up 2.3 %

DVA stock opened at $158.03 on Wednesday. The stock has a market cap of $12.96 billion, a P/E ratio of 17.05, a P/E/G ratio of 0.87 and a beta of 0.89. The company has a current ratio of 1.37, a quick ratio of 1.33 and a debt-to-equity ratio of 15.78. The stock’s fifty day simple moving average is $157.34 and its two-hundred day simple moving average is $147.23. DaVita Inc. has a 1-year low of $84.64 and a 1-year high of $168.50.

DaVita (NYSE:DVA) last issued its quarterly earnings results on Tuesday, October 29th. The company reported $2.59 earnings per share for the quarter, missing analysts’ consensus estimates of $2.76 by ($0.17). DaVita had a return on equity of 88.18% and a net margin of 6.53%. The company had revenue of $3.26 billion during the quarter, compared to analysts’ expectations of $3.25 billion. During the same period last year, the firm posted $2.85 earnings per share. DaVita’s quarterly revenue was up 4.6% compared to the same quarter last year. Analysts expect that DaVita Inc. will post 9.71 EPS for the current year.

About DaVita

DaVita Inc provides kidney dialysis services for patients suffering from chronic kidney failure in the United States. The company operates kidney dialysis centers and provides related lab services in outpatient dialysis centers. It also offers outpatient, hospital inpatient, and home-based hemodialysis services; operates clinical laboratories that provide routine laboratory tests for dialysis and other physician-prescribed laboratory tests for ESRD patients; and management and administrative services to outpatient dialysis centers.